Asset
AVUTOMETINIB
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06072781 | phase3 | recruiting | 2024-03-18 | 2028-10-15 | Verastem, Inc. | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer |
| NCT04620330 | phase2 | completed | 2020-12-31 | 2023-08-29 | Verastem, Inc. | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer |
| NCT04625270 | phase2 | active_not_recruiting | 2020-12-21 | 2024-11-15 | Verastem, Inc. | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation |
| NCT06682572 | phase2 | active_not_recruiting | 2024-10-30 | 2025-12-01 | Verastem, Inc. | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients |
| NCT07747506 | phase2 | not_yet_recruiting | 2026-08-03 | 2027-08-01 | Verastem, Inc. | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) |
FDA applications (0)
This company has no applications containing this asset.